LY3321367

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Breast Cancer (HR+HER2-)Cutaneous MelanomaMicrosatellite Instability-High (MSI-H) Solid TumorsPancreatic CancerSolid Tumor

Phase 1

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

CompletedNCT02791334

Eli Lilly and CompanyBreast Cancer (HR+HER2-), Cutaneous Melanoma, Microsatellite Instability-High (MSI-H) Solid Tumors +2

Start: 2016-06-29End: 2024-06-27Updated: 2024-09-27

A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

CompletedNCT03099109

Eli Lilly and CompanySolid Tumor

Start: 2017-04-12End: 2023-08-30Updated: 2023-10-17

Related Papers

On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.

2023-01-1219 citations

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

European Journal of Cancer2021-09-2724 citations

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Clinical Cancer Research2020-11-2345 citations

Abstract 2753: The molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy

Cancer Research2019-07-018 citations

Abstract 2753: The molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy

Cancer Chemistry2019-07-013 citations

A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers.

Journal of Clinical Oncology2019-03-1085 citations

Abstract CT018: Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents

Cancer Research2018-07-012 citations

Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054

Cancer Research2018-07-01

Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model

Cancer Research2017-07-01